These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31766720)

  • 21. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14.
    Kam CM; Tauber AL; Levonis SM; Schweiker SS
    Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo.
    Thomas C; Ji Y; Lodhi N; Kotova E; Pinnola AD; Golovine K; Makhov P; Pechenkina K; Kolenko V; Tulin AV
    EBioMedicine; 2016 Nov; 13():90-98. PubMed ID: 27727003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lu G; Nie W; Xin M; Meng Y; Gu J; Miao H; Cheng X; Chan ASC; Zou Y
    Eur J Med Chem; 2022 Dec; 243():114790. PubMed ID: 36183505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors.
    Zhao Y; Wang XG; Ma ZY; Xiong GL; Yang ZJ; Cheng Y; Lu AP; Huang ZJ; Cao DS
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 33940596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
    Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
    Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer.
    Hu XL; Feng JH; Pham TA; Ma HY; Ma MX; Song R; Shen W; Xiong F; Zhang XQ; Ye WC; Wang H
    Phytomedicine; 2018 Nov; 50():88-98. PubMed ID: 30466996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
    Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
    Bioorg Med Chem Lett; 2021 Jan; 31():127710. PubMed ID: 33246105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold.
    Elmasry GF; Aly EE; Awadallah FM; El-Moghazy SM
    Bioorg Chem; 2019 Jun; 87():655-666. PubMed ID: 30952061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
    Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
    Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
    Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
    J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
    Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
    Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structurally unique PARP-1 inhibitors for the treatment of prostate cancer.
    Divan A; Sibi MP; Tulin A
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00586. PubMed ID: 32342655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent.
    Kumar C; P T V L; Arunachalam A
    Comput Biol Chem; 2019 Jun; 80():314-323. PubMed ID: 31078910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of novel PARP-1 inhibitors by structure-based virtual screening.
    Hannigan K; Kulkarni SS; Bdzhola VG; Golub AG; Yarmoluk SM; Talele TT
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5790-4. PubMed ID: 24074844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
    Tian Y; Xie Z; Liao C
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling of the Enzyme-Substrate Complexes of Human Poly(ADP-Ribose) Polymerase 1.
    Nilov DK; Pushkarev SV; Gushchina IV; Manasaryan GA; Kirsanov KI; Švedas VK
    Biochemistry (Mosc); 2020 Jan; 85(1):99-107. PubMed ID: 32079521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
    Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
    Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
    [No Abstract]   [Full Text] [Related]  

  • 39. Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer.
    Okunlola FO; Olotu FA; Soliman MES
    J Biomol Struct Dyn; 2022; 40(21):10878-10886. PubMed ID: 34463214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors.
    Li S; Li XY; Zhang TJ; Zhu J; Xue WH; Qian XH; Meng FH
    Bioorg Chem; 2020 Mar; 96():103575. PubMed ID: 31962202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.